Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)

Exclusion Criteria

• •mRS score greater than 1 point before the onset;
• •Receiving neuroprotective agents, such as edaravone, edaravone dextrocamphorol, butylphthalein, etc. after the onset;
• •Bleeding or other pathological brain disorders, such as vascular malformations, tumors, abscesses, or other common non-ischemic brain diseases (such as multiple sclerosis), detected by CT/MRI;
• •History of clotting disorders, systemic bleeding, thrombocytopenia, or neutropenia;
• •Severe hepatic or renal insufficiency (severe hepatic insufficiency refers to the ALT or AST levels above 3 times the upper limit of normal; severe renal insufficiency refers to the creatinine levels above 2 times the upper limit of normal);
• •Allergic to Shuxuening injection or preparations containing ginkgo biloba (ginkgo biloba extract);
• •Women who are pregnant or breastfeeding, and women of childbearing age who have a negative pregnancy test but refuse to take effective contraceptive measures;
• •Participation in another clinical trial with an experimental product during the last 30 days;
• •Other participants deemed unsuitable for participation in this study by the investigator.